CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.
  
  LEARNING OBJECTIVES

  • Develop a long-term care plan for patients diagnosed with metastatic colorectal cancer (CRC), considering biomarker profile, tumor location, exposure to prior systemic therapy, symptomatology, performance status and personal goals of treatment.
  • Evaluate recently presented clinical research findings applicable to the optimal selection and sequencing of systemic therapy for patients with advanced CRC or gastric/gastroesophageal cancer, and consider how these data sets affect current clinical decision-making.
  • Describe the published research data with immune checkpoint inhibitors alone or in combination with chemotherapy for gastric, esophageal or gastroesophageal junction (GEJ) cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
  • Appraise the role of immunotherapy for advanced CRC, and identify patients who may be appropriate for this therapy.
  • Recognize the recent FDA approval of trastuzumab deruxtecan for patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen.
  • Assess published research data documenting the efficacy of combined BRAF/MEK/EGFR inhibition for patients with relapsed/refractory CRC and a BRAF V600E mutation to optimally incorporate this therapeutic strategy into clinical algorithms.
  • Evaluate the utility of HER2 status, PD-L1 combined positive score, microsatellite instability status, clinical factors and patient preferences in the selection and sequencing of systemic therapy for locally advanced or metastatic gastric, GEJ, esophageal and colorectal cancer.
  • Consider available and emerging data with novel agents currently being investigated for gastrointestinal cancers, and refer eligible patients for clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Chloe E Atreya, MD, PhD
  Associate Professor in Residence
  Gastrointestinal Oncology Program
  University of California, San Francisco
  Hellen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pionyr Immunotherapeutics; Research Funding (Institution): Bristol-Myers Squibb Company, Gossamer Bio, Guardant Health, Kura Oncology, Merck, Novartis.
  
  Dustin Deming, MD
  ACI/Schwenn Family Associate Professor
  University of Wisconsin
  School of Medicine and Public Health
  Madison, Wisconsin
  
  Advisory Committee: Acrotech Biopharma, Bayer HealthCare Pharmaceuticals, MEI Pharma Inc, Pfizer Inc, Promega Corporation; Contracted Research: Arcus Biosciences, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck.
  
  Eric Van Cutsem, MD, PhD
  Professor of Medicine
  Digestive Oncology
  University Hospitals Leuven
  Leuven, Belgium
  
  Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, GlaxoSmithKline, Halozyme Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Pierre Fabre, Roche Laboratories Inc, Servier, Sirtex Medical Ltd, Taiho Oncology Inc; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Roche Laboratories Inc, Servier.
  
  Zev Wainberg, MD, MSc
  Co-Director GI Oncology Program
  Director of Early Phase Clinical Research
  Jonsson Comprehensive Cancer Center, UCLA School of Medicine
  Los Angeles, California
  
  Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Molecular Templates; Contracted Research: Arcus Biosciences, Five Prime Therapeutics Inc, Novartis, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Lilly, Merck and Taiho Oncology Inc.
  
  Release date: September 2021
  Expiration date: September 2022